Global Financial Private Capital LLC lowered its stake in shares of Stryker Co. (NYSE:SYK) by 25.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,971 shares of the medical technology company’s stock after selling 5,672 shares during the period. Global Financial Private Capital LLC’s holdings in Stryker were worth $2,663,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Northwest Wealth Management LLC lifted its holdings in Stryker by 103.6% during the fourth quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after buying an additional 86 shares during the period. Horan Securities Inc. purchased a new stake in shares of Stryker during the 4th quarter valued at $30,000. Moody National Bank Trust Division purchased a new stake in shares of Stryker during the 4th quarter valued at $32,000. Exane Derivatives purchased a new stake in shares of Stryker during the 4th quarter valued at $39,000. Finally, Capital Investment Advisory Services LLC purchased a new stake in shares of Stryker during the 4th quarter valued at $46,000. Institutional investors own 74.99% of the company’s stock.
Several brokerages have recently commented on SYK. Zacks Investment Research upgraded Stryker from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Monday, November 26th. Oppenheimer set a $170.00 price objective on Stryker and gave the company a “hold” rating in a report on Friday, November 9th. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a report on Friday, November 9th. Deutsche Bank began coverage on Stryker in a report on Wednesday, January 2nd. They set a “buy” rating and a $179.00 price objective for the company. Finally, Evercore ISI upgraded Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price objective for the company in a report on Wednesday, January 2nd. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $185.37.
Shares of SYK stock opened at $183.53 on Tuesday. The firm has a market capitalization of $68.34 billion, a P/E ratio of 25.11, a PEG ratio of 2.25 and a beta of 0.86. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. Stryker Co. has a 1 year low of $144.75 and a 1 year high of $183.96.
Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.15 by $0.03. The company had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. Analysts forecast that Stryker Co. will post 8.12 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.52 dividend. The ex-dividend date is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a yield of 1.13%. Stryker’s dividend payout ratio (DPR) is 28.45%.
In related news, insider Timothy J. Scannell sold 9,332 shares of the firm’s stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $161.60, for a total value of $1,508,051.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael Damon Hutchinson sold 15,995 shares of the firm’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. Insiders sold a total of 43,259 shares of company stock valued at $7,515,747 in the last 90 days. 7.30% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2019/02/12/global-financial-private-capital-llc-has-2-66-million-holdings-in-stryker-co-syk.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.